1477524-28-9

Basic information

• Product Name: methyl 2-(4-(4'-((5-cyclobutyl-1,3,4-oxadiazol-2-yl)amino)-[1,1'-biphenyl]-4-yl)-2-oxabicyclo[2.2.2]octan-1-yl)acetate
• Synonyms: methyl 2-(4-(4'-((5-cyclobutyl-1,3,4-oxadiazol-2-yl)amino)-[1,1'-biphenyl]-4-yl)-2-oxabicyclo[2.2.2]octan-1-yl)acetate
• CAS NO: 1477524-28-9
• Molecular Weight: 473.572
• Mol File: 1477524-28-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl 2-(4-(4'-((5-cyclobutyl-1,3,4-oxadiazol-2-yl)amino)-[1,1'-biphenyl]-4-yl)-2-oxabicyclo[2.2.2]octan-1-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(4-(4'-((5-cyclobutyl-1,3,4-oxadiazol-2-yl)amino)-[1,1'-biphenyl]-4-yl)-2-oxabicyclo[2.2.2]octan-1-yl)acetate(1477524-28-9)
• EPA Substance Registry System: methyl 2-(4-(4'-((5-cyclobutyl-1,3,4-oxadiazol-2-yl)amino)-[1,1'-biphenyl]-4-yl)-2-oxabicyclo[2.2.2]octan-1-yl)acetate(1477524-28-9)

Safety Data

• Hazardous Substances Data: 1477524-28-9(Hazardous Substances Data)

Upstream product

• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 1384265-30-8 methyl 1-(4-bromophenyl)-4-oxocyclohexane-1-carboxylate 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 
• 1477524-08-5 methyl 2-(4-(4-bromophenyl)-2-oxabicyclo[2.2.2]octan-1-yl)acetate 
• 98069-56-8 cyclobutanecarboxylic acid hydrazide 
• 1477524-24-5 methyl 2-(4-(4'-(2-(cyclobutanecarbonyl)hydrazinecarbothioamido)biphenyl-4-yl)-2-oxabicyclo[2.2.2]octan-1-yl)acetate 
• 1477524-05-2 (8-(4-bromophenyl)-1,4-dioxaspiro[4.5]decan-8-yl)methanol 
• 1477524-04-1 methyl 8-(4-bromophenyl)-1,4-dioxaspiro[4.5]decane-8-carboxylate 

Downstream Products

• 1477523-87-7 2-(4-(4′-(5-cyclobutyl-1,3,4-oxadiazol-2-ylamino)-[1,1'-biphenyl]-4-yl)-2-oxabicyclo[2.2.2]octan-1-yl)acetic acid 

Relevant articles and documents

Successful strategies for mitigation of a preclinical signal for phototoxicity in a dgat1 inhibitor

Diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor Pradigastat (1) was shown to be effective at decreasing postprandial triglyceride levels in a patient population with familial chylomicronemia syndrome (FCS). Although pradigastat does not cause photosensitization in humans at the high clinical dose of 40 mg, a positive signal was observed in preclinical models of phototoxicity. Herein, we describe a preclinical phototoxicity mitigation strategy for diarylamine containing molecules utilizing the introduction of an amide or suitable heterocyclic function. This strategy led to the development of two second-generation compounds with low risk of phototoxicity, disparate exposure profiles, and comparable efficacy to 1 in a rodent lipid bolus model for post-prandial plasma triglycerides.